Natalizumab treatment reduces endothelial activity in MS patients

Journal of Neuroimmunology

Volumn 227, Issue 1-2, 2010, Pages 190-194

  Millonig, Alban ^a   Hegen, Harald ^a   Di Pauli, Franziska ^a   Ehling, Rainer ^a   Gneiss, Claudia ^a   Hoelzl, Martina ^a   Künz, Bettina ^a   Lutterotti, Andreas ^a   Rudzki, Dagmar ^a   Berger, Thomas ^a   Reindl, Markus ^a   Deisenhammer, Florian ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Multiple sclerosis; Natalizumab; Neutralizing antibodies; SVCAM; Vascular cell adhesion molecule 1; Very late activating antigen 4

Indexed keywords

BETA INTERFERON; BETA INTERFERON 1A; BETA INTERFERON 1B; NATALIZUMAB; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VERY LATE ACTIVATION ANTIGEN 4; BIOLOGICAL MARKER; MONOCLONAL ANTIBODY;

ARTICLE; B LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; ENDOTHELIUM; HUMAN; HUMAN CELL; LEUKOCYTE MOTILITY; LYMPHOCYTE SUBPOPULATION; MONOCYTE; MULTIPLE SCLEROSIS; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; TREATMENT DURATION; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; BLOOD; COMPARATIVE STUDY; FOLLOW UP; IMMUNOLOGY; MIGRATION INHIBITION; PATHOLOGY; VASCULAR ENDOTHELIUM;

ANTIBODIES, MONOCLONAL; BIOLOGICAL MARKERS; CELL MIGRATION INHIBITION; ENDOTHELIUM, VASCULAR; FOLLOW-UP STUDIES; HUMANS; INTEGRIN ALPHA4BETA1; MULTIPLE SCLEROSIS; VASCULAR CELL ADHESION MOLECULE-1; ANTIBODIES, MONOCLONAL, HUMANIZED;

EID: 77956650118     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2010.07.012     Document Type: Article

References (38)

1. Brosnan C.F., Cannella B., Battistini L., Raine C.S. Cytokine localization in multiple sclerosis lesions: correlation with adhesion molecule expression and reactive nitrogen species. Neurology 1995, 45:S16-S21.
2. Calabresi P.A., Pelfrey C.M., Tranquill L.R., Maloni H., McFarland H.F. VLA-4 expression on peripheral blood lymphocytes is downregulated after treatment of multiple sclerosis with interferon beta. Neurology 1997, 49:1111-1116.
3. Calabresi P.A., Tranquill L.R., Dambrosia J.M., Stone L.A., Maloni H., Bash C.N., Frank J.A., McFarland H.F. Increases in soluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated with interferon beta-1b. Ann. Neurol. 1997, 41:669-674.
4. Calabresi P.A., Prat A., Biernacki K., Rollins J., Antel J.P. T lymphocytes conditioned with Interferon beta induce membrane and soluble VCAM on human brain endothelial cells. J. Neuroimmunol. 2001, 115:161-167.
5. Cannella B., Raine C.S. The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann. Neurol. 1995, 37:424-435.
6. Deisenhammer F. Neutralizing antibodies to interferon-beta and other immunological treatments for multiple sclerosis: prevalence and impact on outcomes. CNS Drugs 2009, 23:379-396.
7. Deisenhammer F., Mayringer I., Harvey J., Dilitz E., Gasse T., Stadlbauer D., Reindl M., Berger T. A comparative study of the relative bioavailability of different interferon beta preparations. Neurology 2000, 54:2055-2060.
8. Engelhardt B., Ransohoff R.M. The ins and outs of T-lymphocyte trafficking to the CNS: anatomical sites and molecular mechanisms. Trends Immunol. 2005, 26:485-495.
9. Garton K.J., Gough P.J., Philalay J., Wille P.T., Blobel C.P., Whitehead R.H., Dempsey P.J., Raines E.W. Stimulated shedding of vascular cell adhesion molecule 1 (VCAM-1) is mediated by tumor necrosis factor-alpha-converting enzyme (ADAM 17). J. Biol. Chem. 2003, 278:37459-37464.
10. Giovannoni G., Lai M., Thorpe J., Kidd D., Chamoun V., Thompson A.J., Miller D.H., Feldmann M., Thompson E.J. Longitudinal study of soluble adhesion molecules in multiple sclerosis: correlation with gadolinium enhanced magnetic resonance imaging. Neurology 1997, 48:1557-1565.
11. Gneiss C., Brugger M., Millonig A., Fogdell-Hahn A., Rudzki D., Hillert J., Berger T., Reindl M., Deisenhammer F. Comparative study of four different assays for the detection of binding antibodies against interferon-beta. Mult. Scler. 2008, 14:830-836.
12. Graber J., Zhan M., Ford D., Kursch F., Francis G., Bever C., Panitch H., Calabresi P.A., Dhib-Jalbut S. Interferon-beta-1a induces increases in vascular cell adhesion molecule: implications for its mode of action in multiple sclerosis. J. Neuroimmunol. 2005, 161:169-176.
13. Hartung H.P., Reiners K., Archelos J.J., Michels M., Seeldrayers P., Heidenreich F., Pflughaupt K.W., Toyka K.V. Circulating adhesion molecules and tumor necrosis factor receptor in multiple sclerosis: correlation with magnetic resonance imaging. Ann. Neurol. 1995, 38:186-193.
14. Hummel V., Kallmann B.A., Wagner S., Fuller T., Bayas A., Tonn J.C., Benveniste E.N., Toyka K.V., Rieckmann P. Production of MMPs in human cerebral endothelial cells and their role in shedding adhesion molecules. J. Neuropathol. Exp. Neurol. 2001, 60:320-327.
15. Hurwitz E., Stancovski I., Sela M., Yarden Y. Suppression and promotion of tumor growth by monoclonal antibodies to ErbB-2 differentially correlate with cellular uptake. Proc. Natl. Acad. Sci. U.S.A. 1995, 92:3353-3357.
16. Jensen J., Krakauer M., Sellebjerg F. Cytokines and adhesion molecules in multiple sclerosis patients treated with interferon-beta1b. Cytokine 2005, 29:24-30.
17. Kallmann B.A., Hummel V., Lindenlaub T., Ruprecht K., Toyka K.V., Rieckmann P. Cytokine-induced modulation of cellular adhesion to human cerebral endothelial cells is mediated by soluble vascular cell adhesion molecule-1. Brain 2000, 123(Pt 4):687-697.
18. Khademi M., Bornsen L., Rafatnia F., Andersson M., Brundin L., Piehl F., Sellebjerg F., Olsson T. The effects of natalizumab on inflammatory mediators in multiple sclerosis: prospects for treatment-sensitive biomarkers. Eur. J. Neurol. 2009, 16:528-536.
19. Kleinschmidt-DeMasters B.K., Tyler K.L. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N. Engl. J. Med. 2005, 353:369-374.
20. Kraus J., Engelhardt B., Chatzimanolis N., Bauer R., Tofighi J., Kuehne B.S., Laske C., Stolz E., Frielinghaus P., Schaefer C., Blaes F., Traupe H., Kaps M., Oschmann P. Cell surface bound and soluble adhesion molecules in CSF and blood in multiple sclerosis: correlation with MRI-measures of subclinical disease severity and activity. J. Neuroimmunol. 2002, 122:175-185.
21. Langer-Gould A., Atlas S.W., Green A.J., Bollen A.W., Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N. Engl. J. Med. 2005, 353:375-381.
22. Man S., Tucky B., Bagheri N., Li X., Kochar R., Ransohoff R.M. alpha4 Integrin/FN-CS1 mediated leukocyte adhesion to brain microvascular endothelial cells under flow conditions. J. Neuroimmunol. 2009, 210:92-99.
23. Matusevicius D., Kivisakk P., Navikas V.V., Tian W., Soderstrom M., Fredrikson S., Link H. Influence of IFN-beta1b (Betaferon) on cytokine mRNA profiles in blood mononuclear cells and plasma levels of soluble VCAM-1 in multiple sclerosis. Eur. J. Neurol. 1998, 5:265-275.
24. Miller D.H., Khan O.A., Sheremata W.A., Blumhardt L.D., Rice G.P., Libonati M.A., Willmer-Hulme A.J., Dalton C.M., Miszkiel K.A., O'Connor P.W. A controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 2003, 348:15-23.
25. Myers T.J., Brennaman L.H., Stevenson M., Higashiyama S., Russell W.E., Lee D.C., Sunnarborg S.W. Mitochondrial reactive oxygen species mediate GPCR-induced TACE/ADAM17-dependent transforming growth factor-alpha shedding. Mol. Biol. Cell 2009, 20:5236-5249.
26. Oppermann K., Pilz G., Wipfler P., Sulzer C., Afazel S., Haschke-Becher E., Kunz A., Golaszewski S., Ladurner G., Kraus J. Short-term decrease of soluble adhesion molecules during natalizumab treatment. Mult. Scler. 2009, 15:133.
27. Polman C.H., O'Connor P.W., Havrdova E., Hutchinson M., Kappos L., Miller D.H., Phillips J.T., Lublin F.D., Giovannoni G., Wajgt A., Toal M., Lynn F., Panzara M.A., Sandrock A.W. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 2006, 354:899-910.
28. Rieckmann P., Altenhofen B., Riegel A., Baudewig J., Felgenhauer K. Soluble adhesion molecules (sVCAM-1 and sICAM-1) in cerebrospinal fluid and serum correlate with MRI activity in multiple sclerosis. Ann. Neurol. 1997, 41:326-333.
29. Rowinsky E.K. The erbB family: targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors. Annu. Rev. Med. 2004, 55:433-457.
30. Shao M.X., Nadel J.A. Neutrophil elastase induces MUC5AC mucin production in human airway epithelial cells via a cascade involving protein kinase C, reactive oxygen species, and TNF-alpha-converting enzyme. J. Immunol. 2005, 175:4009-4016.
31. Singh R.J., Mason J.C., Lidington E.A., Edwards D.R., Nuttall R.K., Khokha R., Knauper V., Murphy G., Gavrilovic J. Cytokine stimulated vascular cell adhesion molecule-1 (VCAM-1) ectodomain release is regulated by TIMP-3. Cardiovasc. Res. 2005, 67:39-49.
32. Sixt M., Bauer M., Lammermann T., Fassler R. Beta1 integrins: zip codes and signaling relay for blood cells. Curr. Opin. Cell Biol. 2006, 18:482-490.
33. Stuve O., Marra C.M., Jerome K.R., Cook L., Cravens P.D., Cepok S., Frohman E.M., Phillips J.T., Arendt G., Hemmer B., Monson N.L., Racke M.K. Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann. Neurol. 2006, 59:743-747.
34. Stuve O., Marra C.M., Jerome K.R., Cook L., Cravens P.D., Cepok S., Frohman E.M., Phillips J.T., Arendt G., Hemmer B., Monson N.L., Racke M.K. Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann. Neurol. 2006, 59:743-747.
35. Van A.G., Van R.M., Sciot R., Dubois B., Vermeire S., Noman M., Verbeeck J., Geboes K., Robberecht W., Rutgeerts P. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N. Engl. J. Med. 2005, 353:362-368.
36. Woodside D.G., Kram R.M., Mitchell J.S., Belsom T., Billard M.J., McIntyre B.W., Vanderslice P. Contrasting roles for domain 4 of VCAM-1 in the regulation of cell adhesion and soluble VCAM-1 binding to integrin alpha4beta1. J. Immunol. 2006, 176:5041-5049.
37. Yednock T.A., Cannon C., Fritz L.C., Sanchez-Madrid F., Steinman L., Karin N. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 1992, 356:63-66.
38. Zhang Z., Oliver P., Lancaster J.R., Schwarzenberger P.O., Joshi M.S., Cork J., Kolls J.K. Reactive oxygen species mediate tumor necrosis factor alpha-converting, enzyme-dependent ectodomain shedding induced by phorbol myristate acetate. FASEB J. 2001, 15:303-305.